Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET

William B. Eubank, David A. Mankoff, Hubert J. Vesselle, Janet F. Eary, Erin K. Schubert, Lisa K. Dunnwald, Skyler K. Lindsley, Julie R. Gralow, Mary M. Austin-Seymour, Georgianna K. Ellis, Robert B Livingston

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Cases of recurrence of breast cancer can pose considerable diagnostic and therapeutic challenges for the oncologic team. The prognosis and management decisions are based on knowledge of the true extent of disease. Conventional staging methods, including physical examination, assessment of levels of tumor markers, cross-sectional imaging, and bone scintigraphy, may not reliably demonstrate the extent of disease in all cases. Physical examination and cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging) can be problematic because (a) the sequelae of previous surgery and radiation therapy can be difficult to distinguish from recurrent neoplasms and (b) early metastatic disease (small lesions) can be difficult to distinguish from benign lesions that are too small to characterize. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help clarify inconclusive findings from physical examination and cross-sectional imaging. FDG PET is more sensitive than CT in detection of lymphatic spread of disease to locoregional and mediastinal nodes. Metastases at distant sites including the lung, bone, and the liver are also readily detected at FDG PET. FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases.

Original languageEnglish (US)
Pages (from-to)5-17
Number of pages13
JournalRadiographics
Volume22
Issue number1
StatePublished - Jan 2002
Externally publishedYes

Fingerprint

Fluorine
Deoxyglucose
Positron-Emission Tomography
Breast Neoplasms
Physical Examination
Recurrence
Tomography
Bone and Bones
Lymphatic Diseases
Tumor Biomarkers
Radionuclide Imaging
Radiotherapy
Magnetic Resonance Imaging
Neoplasm Metastasis
Lung
Liver
Therapeutics
Neoplasms

Keywords

  • Breast neoplasms, diagnosis, 00.32
  • Breast neoplasms, metastases, 33
  • Breast neoplasms, PET, 00.12163
  • Breast neoplasms, radionuclide studies, 00.12163, 00.12166
  • Fluorine, radioactive, 00.12163, 00.12166

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Eubank, W. B., Mankoff, D. A., Vesselle, H. J., Eary, J. F., Schubert, E. K., Dunnwald, L. K., ... Livingston, R. B. (2002). Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics, 22(1), 5-17.

Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. / Eubank, William B.; Mankoff, David A.; Vesselle, Hubert J.; Eary, Janet F.; Schubert, Erin K.; Dunnwald, Lisa K.; Lindsley, Skyler K.; Gralow, Julie R.; Austin-Seymour, Mary M.; Ellis, Georgianna K.; Livingston, Robert B.

In: Radiographics, Vol. 22, No. 1, 01.2002, p. 5-17.

Research output: Contribution to journalArticle

Eubank, WB, Mankoff, DA, Vesselle, HJ, Eary, JF, Schubert, EK, Dunnwald, LK, Lindsley, SK, Gralow, JR, Austin-Seymour, MM, Ellis, GK & Livingston, RB 2002, 'Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET', Radiographics, vol. 22, no. 1, pp. 5-17.
Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics. 2002 Jan;22(1):5-17.
Eubank, William B. ; Mankoff, David A. ; Vesselle, Hubert J. ; Eary, Janet F. ; Schubert, Erin K. ; Dunnwald, Lisa K. ; Lindsley, Skyler K. ; Gralow, Julie R. ; Austin-Seymour, Mary M. ; Ellis, Georgianna K. ; Livingston, Robert B. / Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. In: Radiographics. 2002 ; Vol. 22, No. 1. pp. 5-17.
@article{9e323aec02304394849c99543ed14954,
title = "Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET",
abstract = "Cases of recurrence of breast cancer can pose considerable diagnostic and therapeutic challenges for the oncologic team. The prognosis and management decisions are based on knowledge of the true extent of disease. Conventional staging methods, including physical examination, assessment of levels of tumor markers, cross-sectional imaging, and bone scintigraphy, may not reliably demonstrate the extent of disease in all cases. Physical examination and cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging) can be problematic because (a) the sequelae of previous surgery and radiation therapy can be difficult to distinguish from recurrent neoplasms and (b) early metastatic disease (small lesions) can be difficult to distinguish from benign lesions that are too small to characterize. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help clarify inconclusive findings from physical examination and cross-sectional imaging. FDG PET is more sensitive than CT in detection of lymphatic spread of disease to locoregional and mediastinal nodes. Metastases at distant sites including the lung, bone, and the liver are also readily detected at FDG PET. FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases.",
keywords = "Breast neoplasms, diagnosis, 00.32, Breast neoplasms, metastases, 33, Breast neoplasms, PET, 00.12163, Breast neoplasms, radionuclide studies, 00.12163, 00.12166, Fluorine, radioactive, 00.12163, 00.12166",
author = "Eubank, {William B.} and Mankoff, {David A.} and Vesselle, {Hubert J.} and Eary, {Janet F.} and Schubert, {Erin K.} and Dunnwald, {Lisa K.} and Lindsley, {Skyler K.} and Gralow, {Julie R.} and Austin-Seymour, {Mary M.} and Ellis, {Georgianna K.} and Livingston, {Robert B}",
year = "2002",
month = "1",
language = "English (US)",
volume = "22",
pages = "5--17",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET

AU - Eubank, William B.

AU - Mankoff, David A.

AU - Vesselle, Hubert J.

AU - Eary, Janet F.

AU - Schubert, Erin K.

AU - Dunnwald, Lisa K.

AU - Lindsley, Skyler K.

AU - Gralow, Julie R.

AU - Austin-Seymour, Mary M.

AU - Ellis, Georgianna K.

AU - Livingston, Robert B

PY - 2002/1

Y1 - 2002/1

N2 - Cases of recurrence of breast cancer can pose considerable diagnostic and therapeutic challenges for the oncologic team. The prognosis and management decisions are based on knowledge of the true extent of disease. Conventional staging methods, including physical examination, assessment of levels of tumor markers, cross-sectional imaging, and bone scintigraphy, may not reliably demonstrate the extent of disease in all cases. Physical examination and cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging) can be problematic because (a) the sequelae of previous surgery and radiation therapy can be difficult to distinguish from recurrent neoplasms and (b) early metastatic disease (small lesions) can be difficult to distinguish from benign lesions that are too small to characterize. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help clarify inconclusive findings from physical examination and cross-sectional imaging. FDG PET is more sensitive than CT in detection of lymphatic spread of disease to locoregional and mediastinal nodes. Metastases at distant sites including the lung, bone, and the liver are also readily detected at FDG PET. FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases.

AB - Cases of recurrence of breast cancer can pose considerable diagnostic and therapeutic challenges for the oncologic team. The prognosis and management decisions are based on knowledge of the true extent of disease. Conventional staging methods, including physical examination, assessment of levels of tumor markers, cross-sectional imaging, and bone scintigraphy, may not reliably demonstrate the extent of disease in all cases. Physical examination and cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging) can be problematic because (a) the sequelae of previous surgery and radiation therapy can be difficult to distinguish from recurrent neoplasms and (b) early metastatic disease (small lesions) can be difficult to distinguish from benign lesions that are too small to characterize. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) can help clarify inconclusive findings from physical examination and cross-sectional imaging. FDG PET is more sensitive than CT in detection of lymphatic spread of disease to locoregional and mediastinal nodes. Metastases at distant sites including the lung, bone, and the liver are also readily detected at FDG PET. FDG PET has been proved accurate in restaging cases of recurrent breast cancer and will likely aid in directing therapy in these cases.

KW - Breast neoplasms, diagnosis, 00.32

KW - Breast neoplasms, metastases, 33

KW - Breast neoplasms, PET, 00.12163

KW - Breast neoplasms, radionuclide studies, 00.12163, 00.12166

KW - Fluorine, radioactive, 00.12163, 00.12166

UR - http://www.scopus.com/inward/record.url?scp=0036369753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036369753&partnerID=8YFLogxK

M3 - Article

C2 - 11796893

AN - SCOPUS:0036369753

VL - 22

SP - 5

EP - 17

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 1

ER -